on HBM Healthcare Investments AG (ETR:CH001262)
Swixx BioPharma and Lundbeck Forge Multi-Regional CNS Partnership
HBM Healthcare Investments has announced a significant development involving its portfolio company, Swixx BioPharma. Swixx has entered into a multi-regional distribution and services partnership with Lundbeck, a global leader in brain health. The agreement encompasses the distribution and commercialization of Lundbeck’s central nervous system (CNS) portfolio in South-East Europe, Turkey, and Latin America. This partnership reinforces Swixx's position in the CNS therapeutic area, covering psychiatric and neurological conditions.
The collaboration mirrors an industry trend of outsourcing commercial operations in emerging markets. Swixx, backed by HBM since 2017, exemplifies local expertise and operational excellence, aligning with HBM’s mission to support innovative healthcare ventures.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all HBM Healthcare Investments AG news